The GHRH/GHRP Axis: How Growth Hormone Secretagogues Work

# The GHRH/GHRP Axis: How Growth Hormone Secretagogues Work

For Research Purposes Only -- Not Intended for Human or Animal Consumption

Introduction

Growth hormone (GH) secretion from the anterior pituitary is regulated by a complex interplay of hypothalamic hormones, peripheral signals, and feedback mechanisms. Two classes of research peptides target this system through distinct but complementary mechanisms: GHRH analogues (such as CJC-1295 and Sermorelin) and GH-releasing peptides/GHRPs (such as Ipamorelin, GHRP-2, and GHRP-6).

Understanding the mechanistic differences between these two classes -- and why they are often studied in combination -- requires familiarity with the hypothalamic-pituitary axis and GH secretion physiology.

Hypothalamic Control of GH Secretion

GH secretion is primarily regulated by two hypothalamic hormones with opposing effects:

GHRH (Growth Hormone-Releasing Hormone): A 44-amino acid peptide produced by the arcuate nucleus of the hypothalamus. GHRH stimulates GH synthesis and secretion from somatotroph cells in the anterior pituitary by binding to the GHRH receptor (GHRHR), a Galphas-coupled GPCR that activates the cAMP/PKA pathway.

Somatostatin (SST): A 14- or 28-amino acid peptide produced by the periventricular nucleus. Somatostatin inhibits GH secretion by binding to somatostatin receptors (SSTRs), Galphai-coupled GPCRs that reduce cAMP production and activate potassium channels, hyperpolarizing somatotroph cells.

The pulsatile pattern of GH secretion -- with large pulses occurring primarily during slow-wave sleep -- reflects the alternating dominance of GHRH and somatostatin inputs to the pituitary.

GHRH Analogues: CJC-1295 and Sermorelin

GHRH analogues are synthetic peptides that mimic the action of endogenous GHRH at the GHRHR. They stimulate GH release through the same cAMP/PKA mechanism as endogenous GHRH.

Sermorelin is a 29-amino acid analogue representing the first 29 amino acids of GHRH -- the minimum sequence required for full receptor binding and activation. It has a short half-life of approximately 10-20 minutes due to rapid proteolytic degradation.

CJC-1295 is a modified GHRH analogue with several amino acid substitutions that improve metabolic stability, plus a Drug Affinity Complex (DAC) that enables covalent binding to albumin. This albumin binding extends the half-life from minutes to days, producing sustained GHRH receptor stimulation rather than the pulsatile stimulation of native GHRH.

The extended half-life of CJC-1295 (with DAC) raises GH and IGF-1 levels more persistently than Sermorelin, but also blunts the pulsatile pattern of GH secretion that is characteristic of normal physiology.

GHRPs: Ipamorelin, GHRP-2, and GHRP-6

GH-releasing peptides act through a completely different receptor -- the ghrelin receptor (GHS-R1a) -- rather than the GHRHR. The ghrelin receptor is the endogenous receptor for ghrelin, a stomach-derived hormone that stimulates GH release and appetite.

GHS-R1a is a Galphaq/11-coupled GPCR that activates phospholipase C, generating IP3 and DAG. IP3-mediated calcium release from the endoplasmic reticulum is the proximate trigger for GH vesicle exocytosis from somatotroph cells.

Ipamorelin is a pentapeptide GHRP with high selectivity for GHS-R1a and minimal effects on other hormones (cortisol, prolactin, ACTH). This selectivity profile distinguishes it from GHRP-2 and GHRP-6, which produce more significant cortisol and prolactin elevations at effective doses.

GHRP-6 is a hexapeptide that produces robust GH release but also significantly stimulates appetite through hypothalamic GHS-R1a activation -- an effect mediated by the same receptor that mediates ghrelin's orexigenic (appetite-stimulating) effects.

Synergistic Combination Effects

A key feature of the GHRH/GHRP system is the synergistic interaction between the two receptor classes. When GHRH analogues and GHRPs are administered together, the GH response is substantially greater than the sum of either compound administered alone.

The mechanistic basis for this synergy involves:

1. GHRH (via cAMP/PKA) increases GH synthesis and sensitizes somatotrophs to calcium-mediated exocytosis
2. GHRPs (via IP3/calcium) provide the calcium signal that triggers GH vesicle fusion
3. GHRPs also inhibit somatostatin release from the hypothalamus, removing the primary brake on GH secretion

This synergy is the rationale for the common research practice of combining CJC-1295 with Ipamorelin -- the two compounds work through complementary mechanisms to produce GH release that neither can achieve alone at equivalent doses.

Somatostatin Inhibition

An underappreciated aspect of GHRP pharmacology is their ability to inhibit somatostatin release. GHS-R1a receptors are expressed on somatostatin-producing neurons in the periventricular nucleus, and GHRP activation of these receptors reduces somatostatin secretion.

By reducing somatostatin tone, GHRPs remove the inhibitory brake on GH secretion, amplifying the stimulatory effect of GHRH. This dual mechanism -- direct pituitary stimulation plus hypothalamic somatostatin inhibition -- contributes to the potent GH-releasing effects of GHRPs.

References

1. Frohman, L.A., & Jansson, J.O. (1986). Growth hormone-releasing hormone. Endocrine Reviews, 7(3), 223-253.
2. Kojima, M., et al. (1999). Ghrelin is a growth-hormone-releasing acylated peptide from stomach. Nature, 402(6762), 656-660.
3. Raun, K., et al. (1998). Ipamorelin, the first selective growth hormone secretagogue. European Journal of Endocrinology, 139(5), 552-561.
4. Bowers, C.Y., et al. (1990). On the in vitro and in vivo activity of a new synthetic hexapeptide that acts on the pituitary to specifically release growth hormone. Endocrinology, 114(5), 1537-1545.